Gland Pharma said on Tuesday that it entered into an agreement with the Russian Direct Investment Fund (RDIF) to supply 252 million doses of the COVID-19 vaccine Sputnik V.
The firm said it is exploring a number of partnerships to leverage its manufacturing capabilities to support the global supply of COVID-19 vaccines.
Gland will use drug substations and drug product facilities at its sites in Hyderabad.
Production is expected to begin in the third quarter of 2021, with projected deliveries starting in the fourth quarter of 2021.
Gland Pharma said, under the terms of the agreement, it would first transfer technology of the pharmaceutical substance to the company’s manufacturing facilities. Upon successful technology transfer, it will begin to fill the vials under the aseptic conditions of the narcotics and drug products.
“Gland Pharma’s expertise in the manufacture of sterile injections on a significant scale will assist in establishing a stable supply of the COVID-19 vaccine,” it said in a statement.
In India, Drs. Reddy’s, with whom RDIF has partnered for clinical trials and markets, applied for emergency authorization last month. An expert committee directed the firm to present more data. Shares of Gland Pharma gained 6.95% to close at 65 2718.65 on Tuesday.
Leave a Reply